HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Seok Jin Kim Selected Research

Extranodal NK-T-Cell Lymphoma

1/2021Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.
1/2021Metabolic activity of extranodal NK/T cell lymphoma on 18F-FDG PET/CT according to immune subtyping.
12/2020Avelumab for the treatment of relapsed or refractory extranodal NK/T-cell lymphoma: an open-label phase 2 study.
11/2020Serum-Derived Exosomal MicroRNA Profiles Can Predict Poor Survival Outcomes in Patients with Extranodal Natural Killer/T-Cell Lymphoma.
1/2020Immune subtyping of extranodal NK/T-cell lymphoma: a new biomarker and an immune shift during disease progression.
9/2017Macrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extranodal NK/T-cell lymphoma.
12/2016Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
7/2015Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.
3/2015Serum survivin and vascular endothelial growth factor in extranodal NK/T-cell lymphoma, nasal type: implications for a potential new prognostic indicator.
11/2014Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Seok Jin Kim Research Topics

Disease

64Lymphoma (Lymphomas)
04/2022 - 01/2008
60Neoplasms (Cancer)
04/2022 - 06/2003
37Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
10/2022 - 03/2008
27Multiple Myeloma
09/2021 - 05/2007
18Non-Hodgkin Lymphoma (Lymphosarcoma)
01/2022 - 07/2006
16T-Cell Lymphoma (Lymphoma, T Cell)
01/2021 - 01/2009
14Disease Progression
09/2022 - 02/2008
12Infections
10/2022 - 03/2008
12Extranodal NK-T-Cell Lymphoma
01/2021 - 07/2006
12B-Cell Lymphoma (Lymphoma, B Cell)
11/2019 - 01/2008
11Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
03/2022 - 01/2009
9Neutropenia
06/2020 - 01/2007
8Amyloidosis
01/2022 - 12/2013
7Immunoglobulin Light-chain Amyloidosis
01/2022 - 01/2013
7Marginal Zone B-Cell Lymphoma (MALT Lymphoma)
01/2021 - 04/2010
6Febrile Neutropenia
10/2022 - 08/2003
6Mantle-Cell Lymphoma (Lymphoma, Mantle Cell)
01/2022 - 01/2009
6Fever (Fevers)
09/2020 - 06/2009
6Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2017 - 06/2009
5Hypoxia (Hypoxemia)
01/2021 - 09/2005
5Anemia
01/2020 - 11/2005
4Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
01/2021 - 05/2016
4Hodgkin Disease (Hodgkin's Disease)
06/2020 - 01/2014
4Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
04/2015 - 01/2010
4BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
12/2010 - 01/2007
4Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2010 - 12/2004
3Breast Neoplasms (Breast Cancer)
12/2021 - 01/2008
3Tuberculosis (Tuberculoses)
01/2020 - 08/2012
3Bronchiolitis Obliterans Syndrome
09/2016 - 11/2010
3Lung Neoplasms (Lung Cancer)
12/2015 - 08/2003
3Hepatocellular Carcinoma (Hepatoma)
12/2015 - 04/2004
3Stomach Neoplasms (Stomach Cancer)
12/2015 - 02/2009
3Burkitt Lymphoma (Burkitt's Lymphoma)
04/2015 - 11/2009
3Neoplasm Metastasis (Metastasis)
01/2008 - 01/2006
2Chromosome Aberrations (Chromosome Abnormalities)
09/2022 - 04/2015

Drug/Important Bio-Agent (IBA)

35Rituximab (Mabthera)FDA Link
10/2022 - 03/2008
18Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2022 - 07/2006
16Doxorubicin (Adriamycin)FDA LinkGeneric
10/2022 - 07/2006
15Vincristine (Oncovin)FDA LinkGeneric
10/2022 - 07/2006
13Methotrexate (Mexate)FDA LinkGeneric
01/2022 - 07/2009
13Dexamethasone (Maxidex)FDA LinkGeneric
09/2021 - 05/2007
12Bortezomib (Velcade)FDA Link
12/2021 - 05/2007
12Biomarkers (Surrogate Marker)IBA
08/2021 - 01/2008
11Prednisone (Sone)FDA LinkGeneric
06/2020 - 07/2006
8AnthracyclinesIBA
03/2022 - 08/2011
8Asparaginase (Elspar)FDA Link
11/2020 - 07/2009
8Etoposide (VP 16)FDA LinkGeneric
10/2020 - 12/2002
8DNA (Deoxyribonucleic Acid)IBA
06/2020 - 08/2003
7L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2021 - 01/2014
7RNA (Ribonucleic Acid)IBA
01/2020 - 09/2007
6Proteins (Proteins, Gene)FDA Link
01/2021 - 09/2007
6Cytarabine (Cytosar-U)FDA LinkGeneric
10/2020 - 06/2009
6Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
03/2015 - 04/2004
6Cisplatin (Platino)FDA LinkGeneric
02/2012 - 12/2002
5Pharmaceutical PreparationsIBA
12/2021 - 06/2013
5pembrolizumabIBA
04/2021 - 01/2017
5Amyloid (Amyloid Fibrils)IBA
01/2021 - 01/2013
5Ferritins (Ferritin)IBA
09/2020 - 01/2005
5Thalidomide (Thalomid)FDA Link
12/2019 - 05/2007
4Prednisolone (Predate)FDA LinkGeneric
10/2022 - 07/2009
4Circulating Tumor DNAIBA
04/2022 - 01/2019
4Cell-Free Nucleic AcidsIBA
04/2022 - 01/2019
4ibrutinibIBA
01/2022 - 01/2016
4Bendamustine HydrochlorideFDA Link
01/2022 - 06/2013
4Lenalidomide (CC 5013)FDA Link
09/2021 - 01/2014
4Immune Checkpoint InhibitorsIBA
01/2021 - 01/2020
4Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link
01/2021 - 06/2010
4CytokinesIBA
12/2020 - 01/2016
4LigandsIBA
02/2020 - 03/2010
4Oxaliplatin (Eloxatin)FDA LinkGeneric
02/2020 - 02/2009
4Interleukin-10 (Interleukin 10)IBA
01/2020 - 01/2016
4IfosfamideFDA LinkGeneric
01/2015 - 12/2002
3BI 836826IBA
02/2021 - 10/2020
3B7-H1 AntigenIBA
01/2021 - 02/2020
3Melphalan (Alkeran)FDA LinkGeneric
10/2020 - 09/2010
3IronIBA
01/2020 - 11/2005
3Monoclonal AntibodiesIBA
10/2019 - 03/2008
3ChemokinesIBA
12/2017 - 05/2015
3Immunoglobulin M (IgM)IBA
07/2016 - 09/2007
3Complementary DNA (cDNA)IBA
01/2016 - 03/2014
3Hepatitis B Surface Antigens (HBsAg)FDA Link
11/2015 - 03/2008
3Indicators and Reagents (Reagents)IBA
03/2015 - 12/2004
3Alemtuzumab (Campath)FDA Link
08/2012 - 02/2011
3Imatinib Mesylate (Gleevec)FDA Link
12/2010 - 01/2007
3Leucovorin (Folinic Acid)FDA Link
02/2009 - 04/2006
3Carbonic Anhydrase IXIBA
11/2007 - 12/2004
3Epirubicin (Ellence)FDA LinkGeneric
01/2007 - 04/2006
2MicroRNAs (MicroRNA)IBA
01/2021 - 11/2020

Therapy/Procedure

60Drug Therapy (Chemotherapy)
01/2022 - 08/2003
32Therapeutics
03/2022 - 05/2007
24Stem Cell Transplantation
01/2022 - 01/2009
14Radiotherapy
01/2022 - 07/2006
10Combination Drug Therapy (Combination Chemotherapy)
12/2021 - 12/2002
6Chemoradiotherapy
06/2018 - 12/2009
6Hematopoietic Stem Cell Transplantation
01/2017 - 03/2011
5Aftercare (After-Treatment)
12/2020 - 02/2015
5Salvage Therapy
01/2014 - 02/2009
4Transplantation
10/2021 - 01/2009
3Immunotherapy
08/2021 - 01/2016
3Induction Chemotherapy
01/2021 - 01/2017